Atara Biotherapeutics

Yahoo Finance • 3 hours ago

Bragar Eagel & Squire, P.C. Reminds Atara Biotherapeutics, Inc. Investors They Have Until May 22nd to Seek Lead Plaintiff Role in Class Action Lawsuit

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Atara (ATRA) To Contact Him Directly To Discuss Their Options If you purchased or acquired Atara securities between May 20, 2024 and... Full story

Yahoo Finance • yesterday

DEADLINE ALERT for ATRA, COTY, SMCI, IBRX: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

BENSALEM, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the... Full story

Yahoo Finance • 3 days ago

ATRA INVESTOR REMINDER: Atara Biotherapeutics, Inc. Investors Have Until May 22, 2026 To Seek Lead Plaintiff Role

NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- If you have suffered a loss on your Atara Biotherapeutics, Inc. (“Atara” or the “Company”) (NASDAQ:ATRA) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@k... Full story

Yahoo Finance • 4 days ago

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATRA

NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Atara Biotherapeutics, Inc. (NASDAQ: ATRA) between May 20, 2024 and January 9, 2026, inclusive (the... Full story

Yahoo Finance • 7 days ago

ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATRA

NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Atara Biotherapeutics, Inc. (NASDAQ: ATRA) between May 20, 2024 and January 9, 2026, inclusive (the... Full story

Yahoo Finance • 7 days ago

ATRA SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on Behalf of Atara Biotherapeutics, Inc. Investors - Contact Kirby McInerney LLP by May 22, 2026

NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds investors who purchased Atara Biotherapeutics, Inc. (“Atara” or the “Company”) (NASDAQ:ATRA) securities to contact Lauren Molinaro of Kirby McInerney LLP by email a... Full story

Yahoo Finance • 7 days ago

ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES, April 03, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Atara Biotherapeutics, Inc. (“Atara” or “the Company”) (NASDAQ: ATRA)... Full story

Yahoo Finance • 8 days ago

DEADLINE ALERT for LU, ATRA, and COTY: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

LOS ANGELES, April 02, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the... Full story

Yahoo Finance • 10 days ago

Did You Lose Money Investing in Atara Biotherapeutics, Inc.? Robbins LLP Encourages Investors with Significant Losses to Contact the Firm About Their Rights Against ATRA

SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Atara Biotherapeutics, Inc. (NASDAQ: ATRA) securities between May... Full story

Yahoo Finance • 10 days ago

Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers – ATRA

NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Atara Biotherapeutics, Inc. (“Atara” or the “Company”) (NASDAQ: ATRA) and certain officers.   The class action, filed... Full story

Yahoo Finance • 10 days ago

ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATRA

NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Atara Biotherapeutics, Inc. (NASDAQ: ATRA) between May 20, 20... Full story

Yahoo Finance • 10 days ago

Holzer & Holzer, LLC Reminds Investors of Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Atara Biotherapeutics, Inc. (ATRA), Coty Inc. (COTY), Vital Farms, Inc. (VITL), and Super Micro Computer, Inc. (SMCI)

ATLANTA, March 31, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC reminds investors of the deadline to seek to be appointed lead plaintiff in the following class action lawsuits: Atara Biotherapeutics, Inc. (ATRA) The shareholder class... Full story

Yahoo Finance • 15 days ago

Bronstein, Gewirtz & Grossman LLC Urges Atara Biotherapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

NEW YORK, March 26, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Atara Biotherapeutics, Inc. (NASDAQ: ATRA) an... Full story

Yahoo Finance • 16 days ago

Portnoy Law Firm Announces Class Action on Behalf of Atara Biotherapeutics, Inc. Investors

LOS ANGELES, March 25, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Atara Biotherapeutics, Inc., (“Atara” or the "Company") (NASDAQ: ATRA) investors of a class action on behalf of investors that bought securities between May 20,... Full story

Yahoo Finance • 17 days ago

INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Atara Biotherapeutics, Inc. (ATRA) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm

ATLANTA, March 24, 2026 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Atara Biotherapeutics, Inc. (“Atara”) (NASDAQ: ATRA). The lawsuit alleges that Defendants issued false and misleading statements and/or... Full story

Yahoo Finance • 2 months ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA

NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. (“Atara” or the “Company”) (NASDAQ: ATRA).  Such investors are advised to contact Danielle Peyton at... Full story

Yahoo Finance • 5 months ago

Atara Biotherapeutics GAAP EPS of -$0.32 beats by $0.37, revenue of $3.5M beats by $0.76M

* Atara Biotherapeutics press release [https://seekingalpha.com/pr/20304068-atara-biotherapeutics-announces-third-quarter-financial-results-and-operational-progress] (ATRA [https://seekingalpha.com/symbol/ATRA]): Q3 GAAP EPS of -$0.32 be... Full story

Yahoo Finance • 8 months ago

Tuesday's Insider Activity: Top Buys and Sells in US Stocks Revealed

This article summarizes the most significant insider buys and sells reported for US stocks on Tuesday, August 19, 2025. Top Insider Buys: Atara Biotherapeutics, Inc. (NASDAQ:ATRA) saw Director James Huang purchase 55,000 shares of common... Full story

Yahoo Finance • 8 months ago

Atara biotherapeutics (ATRA) director Huang buys $670k in stock

Director James Huang of Atara Biotherapeutics, Inc. (NASDAQ: NASDAQ:ATRA), a company with a market capitalization of $78.83 million, reported purchasing 55,000 shares of common stock on August 15, 2025. The shares were bought at a weighted... Full story

Yahoo Finance • 8 months ago

Mizuho lowers Atara Biotherapeutics stock price target on delayed tab-cel launch

Investing.com - Mizuho has lowered its price target on Atara Biotherapeutics (NASDAQ:ATRA) to $16.00 from $18.00 while maintaining an Outperform rating on the stock. The company, currently trading at $12.29 with a market cap of $83.52 mill... Full story